Published On: 6/11/2024
EASL 2024 Research: Video Presentation by A. Sidney Barritt IV, MD, MSCR
Lead author and member of the TARGET-NASH steering committee, A. Sidney Barritt IV, MD, MSCR, presented a new Target RWE study analysis at EASL 2024 titled “Real-World Use of Glucagon Like Peptide 1 Receptor Agonist in Patients with MASLD: A Cross-Sectional Analysis from Target NASH.”
The study analyzed the use of GLP-1 receptor agonists in real world patients diagnosed with MASL, metabolic dysfunction-associated steatohepatitis (MASH), and MASLD with cirrhosis – finding that 11% of the adult cohort were prescribe GLP-1 therapy. Watch this video presentation by Dr. Barritt highlighting the important study:
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
Contact:
Kayla Slake
Marketing Manager
984.234.0268 ext 205
More News
-
06/12/2024
Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic Definitions -
06/11/2024
EASL 2024 Research: Video Presentation by Arun J. Sanyal, MBBS, MD -
06/11/2024
EASL 2024 Research: Video Presentation by A. Sidney Barritt IV, MD, MSCR -
06/11/2024
GLP-1 Use and NASH-CHECK Patient-Reported Outcomes Studies from Target RWE Presented at EASL 2024 -
06/04/2024
World’s Largest Liver Disease-Focused Registry Surpasses 400,000 Patient Enrollment Milestone